Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;108(4):450-456.
doi: 10.1111/cge.14752. Epub 2025 Apr 10.

Novel ABCD1 Variants in X-Linked Adrenoleukodystrophy

Sen-Wei Dong  1 , Li-Mei Xiao  1 , Yu-Hao Sun  1 , Gui-He Li  1 , Ying-Xuan Xie  1 , Meng-Wen Wang  1 , Ning Wang  1 , Wan-Jin Chen  1 , Hai-Zhu Chen  1   2   3
Affiliations

Novel ABCD1 Variants in X-Linked Adrenoleukodystrophy

Sen-Wei Dong et al. Clin Genet. 2025 Oct.

Abstract

X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disorder caused by mutations in the ABCD1 gene. We reported the clinical features and genetic findings of 17 X-ALD patients. Fifteen variants were identified, including five novel mutations: c.700dupC (p.Arg234Profs*67), c.743G>A (p.Gly248Asp), c.1469_1471delTGG (p.Val490del), c.1577C>A (p.Thr526Lys), and c.1658T>C (p.Leu553Pro), which were reported for the first time in X-ALD patients. Functional analysis confirmed the pathogenicity of novel variants at the protein and subcellular localization level. The p.Arg234Profs*67 mutant protein was undetectable, likely due to NMD-mediated mRNA degradation. This study expands the mutation spectrum and clinical profile of X-ALD, suggesting a potential correlation between the extent of protein dysfunction and disease severity.

Keywords: ABCD1 gene; X‐linked adrenoleukodystrophy (X‐ALD); adrenomyeloneuropathy (AMN); childhood cerebral ALD (CCALD); protein stability.

PubMed Disclaimer

References

    1. J. Berger, S. Forss‐Petter, and F. S. Eichler, “Pathophysiology of X‐Linked Adrenoleukodystrophy,” Biochimie 98, no. 100 (2014): 135–142, https://doi.org/10.1016/j.biochi.2013.11.023.
    1. M. Engelen and S. Kemp, “Newborn Screening for Adrenoleukodystrophy,” JAMA Pediatrics (2025), https://doi.org/10.1001/jamapediatrics.2024.6771 Epub ahead of print.
    1. X. Zuo and Z. Chen, “From Gene to Therapy: A Review of Deciphering the Role of ABCD1 in Combating X‐Linked Adrenoleukodystrophy,” Lipids in Health and Disease 23, no. 1 (2024): 369, https://doi.org/10.1186/s12944‐024‐02361‐0.
    1. J. Berger and J. Gartner, “X‐Linked Adrenoleukodystrophy: Clinical, Biochemical and Pathogenetic Aspects,” Biochimica et Biophysica Acta 1763, no. 12 (2006): 1721–1732, https://doi.org/10.1016/j.bbamcr.2006.07.010.
    1. J. H. Kim and H. J. Kim, “Childhood X‐Linked Adrenoleukodystrophy: Clinical‐Pathologic Overview and MR Imaging Manifestations at Initial Evaluation and Follow‐Up,” Radiographics 25, no. 3 (2005): 619–631, https://doi.org/10.1148/rg.253045118.

Substances

LinkOut - more resources